000305554 001__ 305554
000305554 005__ 20251102023515.0
000305554 0247_ $$2doi$$a10.1016/j.lungcan.2025.108803
000305554 0247_ $$2pmid$$apmid:41151358
000305554 0247_ $$2ISSN$$a0169-5002
000305554 0247_ $$2ISSN$$a1872-8332
000305554 0247_ $$2altmetric$$aaltmetric:182872401
000305554 037__ $$aDKFZ-2025-02224
000305554 041__ $$aEnglish
000305554 082__ $$a610
000305554 1001_ $$aFaehling, Martin$$b0
000305554 245__ $$aPattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.
000305554 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000305554 3367_ $$2DRIVER$$aarticle
000305554 3367_ $$2DataCite$$aOutput Types/Journal article
000305554 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761746203_3909802
000305554 3367_ $$2BibTeX$$aARTICLE
000305554 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305554 3367_ $$00$$2EndNote$$aJournal Article
000305554 520__ $$aNSCLC with mutations of the KRAS or EGFR gene is associated with a high risk of brain metastases (BRA). There are few data on the prevalence and pattern of BRA and on survival in unselected KRAS or EGFR patients.This real-world analysis (KOMPASS-study) included 326 NSCLC patients with stage IV adenocarcinoma and either KRAS mutation (n = 90), EGFR mutation (n = 87), or no known driver mutation (n = 149). Prevalence, number, and size of BRA, and the effect of BRA on overall survival (OS) were analyzed.The prevalence of BRA was higher in KRAS patients (40 %) or EGFR patients (39 %) than in no-driver patients (27 %). KRAS patients and no-driver patients significantly more often had single BRA, whereas EGFR patients had multiple BRA (median number 1, 2, and 4, respectively). The presence of BRA did not adversely affect OS in KRAS patients (22.3 vs. 19.2 months, HR 0.91) and no-driver patients (8.9 vs. 10.9 months, HR 0.99). EGFR patients with BRA had inferior OS (20.5 vs. 35.5 months, HR 2.70, p = 0.0004). Patients with single BRA had improved OS (22.3 vs. 13.2 months, p = 0.013).The lack of a negative effect of BRA on OS in KRAS patients or no-driver patients may be due to the frequent finding of a single BRA amenable to ablative treatment. The negative effect of BRA on OS in EGFR patients points to a distinct biology of EGFR-mutated NSCLC leading to a characteristic radiological pattern of multiple BRA which are not amenable to ablative treatment.
000305554 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000305554 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305554 650_7 $$2Other$$aCNS metastases
000305554 650_7 $$2Other$$aEGFR
000305554 650_7 $$2Other$$aExon 21
000305554 650_7 $$2Other$$aG12C
000305554 650_7 $$2Other$$aKRAS
000305554 650_7 $$2Other$$aLung cancer
000305554 650_7 $$2Other$$aNumber of brain metastases
000305554 650_7 $$2Other$$aOverall survival
000305554 650_7 $$2Other$$aReal world data
000305554 650_7 $$2Other$$aSize
000305554 7001_ $$aFallscheer, Sabine$$b1
000305554 7001_ $$aSchmiederer, Julia$$b2
000305554 7001_ $$aSträter, Jörn$$b3
000305554 7001_ $$aChristopoulos, Petros$$b4
000305554 7001_ $$0P:(DE-HGF)0$$aLengerke, Claudia$$b5
000305554 7001_ $$aSeifarth, Harald$$b6
000305554 773__ $$0PERI:(DE-600)2025812-4$$a10.1016/j.lungcan.2025.108803$$gVol. 209, p. 108803 -$$p108803$$tLung cancer$$v209$$x0169-5002$$y2025
000305554 909CO $$ooai:inrepo02.dkfz.de:305554$$pVDB
000305554 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000305554 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000305554 9141_ $$y2025
000305554 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000305554 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLUNG CANCER : 2022$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000305554 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLUNG CANCER : 2022$$d2024-12-11
000305554 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK Koordinierungsstelle Tübingen$$x0
000305554 980__ $$ajournal
000305554 980__ $$aVDB
000305554 980__ $$aI:(DE-He78)TU01-20160331
000305554 980__ $$aUNRESTRICTED